Hong Kong, 4 November 2026
Opharmic Technology (HK) Limited is pleased to announce the successful recertification of its Quality Management System (QMS) under ISO 13485:2016.
This independent audit confirms that Opharmic’s quality system continues to meet the internationally recognized requirements for the design, development, and manufacture of medical devices. The recertification reinforces the company’s long-standing commitment to quality, patient safety, and regulatory excellence as it advances its ultrasound platforms toward clinical trials.
ISO 13485:2016 is the global benchmark for medical device quality management systems. Maintaining certification demonstrates that Opharmic’s processes — spanning design controls, risk management, supplier oversight, and production — remain robust and aligned with the expectations of regulators, partners, and clinicians.
The achievement is particularly significant as the company prepares its retinal drug delivery programme (under the MeticTouch® platform) for First-in-Human trials and continues development of other innovative programmes (under the MeticStim® platform). A certified QMS provides a strong foundation for regulatory submissions and manufacturing readiness.
“Successful recertification of our ISO 13485 system reflects the discipline and consistency of our team,” said Dr. Langston Suen, CEO of Opharmic Technology. “As we move into the clinical stage, maintaining the highest quality standards is essential to delivering safe and effective solutions for patients.”
The recertification audit covered the full scope of Opharmic’s quality system. The company will continue to invest in its QMS to support ongoing growth, including clinical unit assembly, validation activities, and international expansion.
This milestone further strengthens Opharmic’s position as a reliable partner for pharmaceutical companies, hospitals, and investors seeking high-quality non-invasive ultrasound technologies.
Opharmic Technology